Rheumatology billing is uniquely difficult because it combines high-cost biologic drug administration (J-codes) with extremely high prior authorization burdens, step therapy requirements that must be documented and tracked per payer, and complex infusion therapy billing that varies between office-based and hospital outpatient settings. A single missing step therapy failure documentation or incorrect J-code can result in a five- or six-figure denial.
To excel in rheumatology medical billing services, proficiency in J-code and biologic drug coding, prior authorization and step therapy tracking, infusion therapy billing (96413, 96415, 96417), and office visit coding (99213–99215) is crucial. Errors in coding or a missed prior authorization can result in five- or six-figure denials, potentially prompting coding audits. Drawing on our proven track record in rheumatology billing, we offer comprehensive support including coding education, timely billing updates, and expertise in recovering previously denied claims.
Billed Right has provided rheumatology billing support since 2006, serving practices across the US from our base in Longwood, Florida.
Common Pain Areas
- Biologic prior authorization denials can stall treatment and delay reimbursement for months.
- Step therapy documentation failures give payers an easy reason to deny a biologic before it's ever administered.
- J-code billing errors for drug administration can turn a correctly delivered infusion into a five- or six-figure denial.
- Infusion therapy coding mistakes on time-based codes like 96413 and 96415 can cost you reimbursable add-on units.
- Medicare Part B vs. Part D coverage confusion for biologics can result in claims billed to the wrong benefit entirely.
Rheumatology Solutions
- Quick turnaround time in Denial management and follow up to appeal any denied biologic or infusion claims. Once the alert is activated, we will follow up within 24-48 hours and appeal any denied claims within the same timeframe.
- Key Performance Indicators (KPI) to demonstrate if your practice is achieving key business objectives.
- We work with all major EMR (electronic medical records)
- Remote login for easy access.
- Quick and smooth transition.
- No negative impact on your daily operation.
- Bilingual representatives are available.
Download Our Brochure
Top Denial Reasons
Missing or Expired Prior Authorization for Biologics
Biologics almost always require prior authorization, and an expired authorization on a recurring infusion schedule is an easy, avoidable denial.
Step Therapy Requirements Not Documented
Payers require proof that first-line treatments like methotrexate failed before approving a biologic, and undocumented step therapy is a guaranteed denial.
Incorrect J-Code for Administered Biologic
Billing the wrong J-code, or a unit count that doesn't match the dose actually administered, is a five- or six-figure risk on a single claim.
Infusion Time Not Documented to Support Add-On Units
96415 and other add-on infusion codes require documented start and stop times, and missing timestamps mean the payer only reimburses the initial hour.
Medicare Part B vs. Part D Coverage Mismatch
Billing a self-administered biologic to Part B, or a physician-administered biologic as a pharmacy claim, results in an outright coverage denial.
Payer-Specific Considerations
Payer rules for rheumatology diverge sharply depending on how a biologic is administered and covered. Medicare Part B covers physician-administered biologics: infusions and in-office injections billed under the appropriate J-code, like J1745 for infliximab or J0717 for certolizumab. Self-administered drugs like Humira (J0135) typically fall under Part D and require a specialty pharmacy, not a medical claim. Medicaid prior authorization requirements for biologics vary significantly by state formulary, so the same drug can require a different documentation packet from state to state. Commercial payers impose strict step therapy protocols requiring documented failure of first-line treatments like methotrexate before approving high-cost biologics such as Humira, Enbrel, or Remicade, and office visit codes (99213–99215) billed alongside an infusion need their own supporting documentation to avoid bundling denials.
What to Expect
Billing Review
We audit recent office visit, infusion, and biologic drug administration claims and show you exactly where revenue is leaking.
Onboarding & EHR Setup
Payer setup and integration with your existing EHR/PM system, no rip-and-replace.
Credentialing Check
We verify provider enrollment status and handle re-credentialing if needed.
Claims Submission Begins
Correctly coded claims go out under full account management, same business day.
Denial Monitoring & Appeals
Denials are flagged and appealed within 24–48 hours of the alert.
Monthly Reporting
KPI dashboards show collections, A/R days, and denial trends every month.
Results Reflected in Our KPIs
Our medical billing solutions keep claims moving and denied claims followed up on, which drives better billing efficiency overall. Our rheumatology billing expertise helps you cut denials and run a tighter revenue cycle.
Frequently Asked Questions
Common J-codes include J1745 for infliximab (Remicade), J0717 for certolizumab pegol (Cimzia), and J0135 for adalimumab (Humira) when administered in-office. Using the wrong J-code, or billing units that don't match the administered dose, is one of the fastest ways to trigger a denial or an audit.
Yes. Nearly every biologic, including Humira, Enbrel, Remicade, and Actemra, requires prior authorization before the first dose, and most payers require renewal on a set schedule. Missing or expired authorization is the leading cause of biologic claim denials we see.
Most commercial payers require documented proof that first-line treatments like methotrexate or other conventional DMARDs were tried and failed before they'll approve a high-cost biologic. That documentation has to be submitted with the prior authorization, not after: an undocumented step therapy failure is an easy denial to avoid.
The core infusion codes are 96413 (initial hour, IV infusion for therapy or prophylaxis) and 96415 (each additional hour), with 96417 used for a sequential infusion of a new drug in the same visit. Documentation must support the actual infusion start and stop times to justify add-on units.
It depends on how the drug is administered. Physician-administered biologics given by infusion or injection in the office, like infliximab, are billed under Medicare Part B using the appropriate J-code. Self-administered biologics like Humira are typically covered under Part D through a specialty pharmacy, not billed on the medical claim at all. Mixing these up is a common coverage denial.
Yes. Office-based infusions are billed under the physician's NPI with physician fee schedule rates, while hospital outpatient infusions are billed under the hospital's provider number with different rates and often stricter medical necessity documentation requirements. The same biologic administered in each setting can be reimbursed very differently.
“I have been extremely pleased and satisfied by the promptness and thoroughness. There is always excellent feedback and quick resolution to any issue.”
More on rheumatology billing.
Rheumatology Coding Updates for 2026: Biologics and J-Code Changes
A rundown of the J-code and prior authorization changes rheumatology practices need to know about this year.
ReadRheumatology Biologic Prior Authorization Checklist
A quick self-audit checklist for step therapy documentation and prior authorization before you submit a biologic claim.
Get itRheumatology Practice Cuts Biologic Denial Rate and Recovers Lost Revenue
A composite look at how a multi-provider rheumatology practice tightened J-code and prior authorization documentation to recover lost revenue.
ReadReady to Strengthen Your Rheumatology Revenue Cycle?
Schedule a conversation with our rheumatology billing team. We will review your current claims, identify where revenue is slipping, and show you exactly what we would do differently.